NCT00912418已完成不适用
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus GM-CSF-in-adjuvant, Followed by Systemic Low-dose-IL-2 Administration, in Patients With High Risk Melanoma.
Craig L Slingluff, Jr2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2000年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Cytotoxic T-cell response to autologous tumor (as measured by staining assay)
研究概览
简要总结
This study is an open-label, pilot study of an autologous tumor cell vaccine.
详细描述
Regimen: A vaccine comprising autologous melanoma cells plus GM-CSF in-adjuvant will be administered intradermally at a single dose. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.
Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have been diagnosed, by cytologic or histologic examination, with stage III or stage IV melanoma, where sufficient resected tumor is available for vaccine preparation (approximately 3 g tumor).
- •Measurable tumor after resection is not required.
- •Patients with up to 3 brain metastases may be included if the metastases are all < 2 cm in diameter, are asymptomatic, and there is no mass effect or they have been treated successfully by surgical excision or by gamma knife radiation therapy.
- •Patients who have had a larger number of brain metastases resected or treated and resolved after gamma knife radiation therapy may be included if their status at the time of study initiation meets these criteria.
- •For those patients with resected melanoma, surgical resections must have been performed within 6 months prior to entry. All patients must have:
- •ECOG performance status 0-1, and, ability and willingness to give informed consent.
- •Laboratory parameters as follows: ANC > 1000/mm3, and Platelets > 100,000 and Hgb >
- •Hepatic: AST and ALT up to 1.5 x upper limits of normal (ULN), Bilirubin within ULN, Alkaline phosphatase up to 1.5 x ULN
- •Renal: Creatinine within ULN
- •Serology: HIV negative, Hepatitis C virus-negative.
- •Patients who are not candidates for interferon, for people who decide not to take interferon, or for people who have failed interferon therapy (those patients who have progressed while on interferon therapy or who experienced a major toxicity while receiving treatment).
排除标准
- •Patients who are currently receiving cytotoxic chemotherapy or radiation therapy, or who have received that therapy within the preceding 4 weeks.
- •Patients who are currently receiving investigational agents, or who have received investigational agents within the preceding 30 days.
- •Patients with known or suspected allergies to any component of the vaccine.
- •Patients receiving the following medications at study entry or within 30 days are excluded:
- •Allergy desensitization injections
- •Corticosteroids, administered parenterally or orally.
- •Topical corticosteroids are acceptable, Any growth factors, Interferons, Interleukin 2 (IL-2).
- •Prior melanoma vaccinations will not be an exclusion criteria if given more than 8 weeks previously, but will be recorded, and data analysis will take this into account.
- •Other investigational drugs or investigational therapy also will not necessarily be an exclusion criteria, but will similarly be recorded and taken into account during data analysis.
- •Pregnancy or the possibility of becoming pregnant during vaccine administration.
- •Female patients of child-bearing potential must have a negative pregnancy test (urinary or serum beta-HCG) prior to administration of the first vaccine dose.
- •Males and females must agree, in the consent form, to use effective birth control methods during the course of vaccination. This is consistent with existing standards of practice for vaccine and chemotherapy protocols.
- •Patients in whom there is a medical contraindication or other potential medical problem in complying with the requirements of the protocol, in the opinion of the investigator.
- •Patients classified according to the New York Heart Association classification system as having Class II, III or IV heart disease.
- •Patients with active connective tissue disease requiring medications, or other severe autoimmune disease.
- •Patients who are actively hyperthyroid.
- •Patients with uncontrolled diabetes.
- •Patients with known allergies to penicillin, streptomycin, and amphotericin B.
结局指标
主要结局
Cytotoxic T-cell response to autologous tumor (as measured by staining assay)
次要结局
- Cytotoxic T-cell response to defined melanoma antigens. 1: Activation antigen expression by lymph node T-cells 2: Delayed-type hypersensitivity response to autologous tumor cells. 3: Antibody response to autologous tumor cells.
研究者
Craig L Slingluff, Jr
Director, Human Immune Therapy Center
University of Virginia
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV MelanomaSarcoma, Clear CellSarcoma, Alveolar Soft PartRenal Cell CarcinomaMelanomaNCT00258687Dana-Farber Cancer Institute12
已完成
1 期
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersDermatitis, AtopicHay FeverNCT00189917Bavarian Nordic60
招募中
1 期
Autologous Tumour Vaccine TrialSolid TumorNCT05807035Vaxine Pty Ltd30
终止
1 期
Pilot Study of GVAX in Colorectal Cancer CellsColorectal CancerNCT01952730Massachusetts General Hospital1
Unknown
早期 1 期
Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast CancerBreast Neoplasm FemaleStage I Breast CancerStage II Breast CancerHormone Receptor Negative NeoplasmHormone Receptor Positive TumorNCT03691311Institut Català d'Oncologia60